US Stock MarketDetailed Quotes

INM InMed Pharmaceuticals

Watchlist
  • 2.0800
  • +0.0100+0.48%
Close Apr 1 16:00 ET
2.51MMarket Cap-0.17P/E (TTM)

InMed Pharmaceuticals Key Stats

InMed Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CAD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q31.601M / 2.005M--
--2024/Q21.682M / 1.518M--
--2024/Q11.243M / 1.895M--
--2023/Q43.126M / 3.039M--
Sep 23, 20222022/Q4698.290K / 969.890K--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q31.601M / 2.005M--
--2024/Q21.682M / 1.518M--
--2024/Q11.243M / 1.895M--
--2023/Q43.126M / 3.039M--
Sep 23, 20222022/Q4698.290K / 969.890K--

Unlock Free Earnings Estimates

InMed Pharmaceuticals Earnings Reports

Read more

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.

Discussing

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More